WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Transplant Product - AR-CSAR CMAP, Concepts (e.g. Graft survival) are denoted by solid round-edged rectangle, Acute Rejection can be assessed at 12 months, urine output is measured as decreased, Therapeutic Efficacy Point is the intersection of Physiolgoical Process, Concepts (e.g. Graft survival) are denoted by solid round-edged rectangle, Serum Creatinine (SCr) is measured as increased, Acute Rejection includes Clinically suspected Acute Rejection, Clinically suspected Acute Rejection can be defined by Serum Creatinine (SCr), Observation or Assessment is used to monitor the state of Physiolgoical Process, Clinically suspected Acute Rejection can be defined by fever, Serum Creatinine (SCr) is measured at post-transplant, Acute Rejection has a detrimental effect on Graft survival, Clinically suspected Acute Rejection can be defined by graft tenderness, Therapeutic Efficacy Point is the intersection of Observation or Assessment, Therapeutic Efficacy Point is the intersection of Therapeutic Intervention, Observation or Assessment is used to monitor the effectiveness of Therapeutic Intervention, Clinically suspected Acute Rejection can be defined by urine output, Main concepts (e.g. Death, Graft Loss) are denoted by Larger bold font with thicker outline, Serum Creatinine (SCr) can be thresholded at ≥ 25% from baseline, defined time points including 14 days